Uy Ear
Stock Analyst at Mizuho
(4.12)
# 502
Out of 5,090 analysts
75
Total ratings
45.65%
Success rate
18.75%
Average return
Main Sectors:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Maintains: Outperform | $20 → $19 | $6.85 | +177.37% | 4 | Dec 2, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $24 → $29 | $27.44 | +5.69% | 15 | Dec 2, 2025 | |
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $32 → $37 | $31.20 | +18.59% | 15 | Nov 28, 2025 | |
| RLMD Relmada Therapeutics | Upgrades: Outperform | $1 → $10 | $4.24 | +135.85% | 2 | Nov 19, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $19 → $26 | $22.26 | +16.80% | 9 | Nov 5, 2025 | |
| ALKS Alkermes | Maintains: Outperform | $40 → $45 | $29.52 | +52.44% | 6 | Oct 27, 2025 | |
| QURE uniQure | Maintains: Outperform | $30 → $60 | $21.33 | +181.29% | 5 | Sep 25, 2025 | |
| MBX MBX Biosciences | Maintains: Outperform | $38 → $56 | $31.97 | +75.16% | 2 | Sep 24, 2025 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $51 → $85 | $19.92 | +326.71% | 2 | May 15, 2025 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $40 | $6.88 | +481.40% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $116 → $140 | $155.51 | -9.97% | 10 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $40 | $201.93 | -80.19% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.55 | +292.16% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $1.22 | +145.90% | 2 | Mar 1, 2023 |
Evolus
Dec 2, 2025
Maintains: Outperform
Price Target: $20 → $19
Current: $6.85
Upside: +177.37%
ACADIA Pharmaceuticals
Dec 2, 2025
Maintains: Neutral
Price Target: $24 → $29
Current: $27.44
Upside: +5.69%
Arcutis Biotherapeutics
Nov 28, 2025
Maintains: Outperform
Price Target: $32 → $37
Current: $31.20
Upside: +18.59%
Relmada Therapeutics
Nov 19, 2025
Upgrades: Outperform
Price Target: $1 → $10
Current: $4.24
Upside: +135.85%
Sarepta Therapeutics
Nov 5, 2025
Upgrades: Outperform
Price Target: $19 → $26
Current: $22.26
Upside: +16.80%
Alkermes
Oct 27, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $29.52
Upside: +52.44%
uniQure
Sep 25, 2025
Maintains: Outperform
Price Target: $30 → $60
Current: $21.33
Upside: +181.29%
MBX Biosciences
Sep 24, 2025
Maintains: Outperform
Price Target: $38 → $56
Current: $31.97
Upside: +75.16%
Tectonic Therapeutic
May 15, 2025
Maintains: Outperform
Price Target: $51 → $85
Current: $19.92
Upside: +326.71%
Cartesian Therapeutics
May 24, 2024
Initiates: Buy
Price Target: $40
Current: $6.88
Upside: +481.40%
Feb 8, 2024
Maintains: Neutral
Price Target: $116 → $140
Current: $155.51
Upside: -9.97%
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $201.93
Upside: -80.19%
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $2.55
Upside: +292.16%
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $1.22
Upside: +145.90%